Zila Begins Proxy Vote on Merger With Tolmar
August 19 2009 - 2:00PM
Business Wire
Zila, Inc. (Nasdaq: ZILA) today announced that Proxy Statements
and Proxies have been mailed to its stockholders in order to allow
them to vote on the proposed merger with a subsidiary of TOLMAR
Holding, Inc. Under the terms of the merger agreement, if approved
by the stockholders, each Zila stockholder would be entitled to
receive $0.45 per share in cash. Tolmar is a privately held,
pharmaceutical research, development, manufacturing and commercial
operations company.
The special meeting of stockholders will be held on Friday,
September 18, 2009, for those stockholders who owned Zila stock on
the record date of August 12, 2009. The meeting will be at 8:00
a.m. local time at the Hampton Inn & Suites, 16620 North
Scottsdale Road, Scottsdale, Arizona 85254.
A copy of the Proxy Statement is available on Zila’s Website at
www.zila.com. Stockholders may vote via:
- the internet at
www.envisionreports.com/ZILA
- telephone by dialing the
toll-free number 1-800-652-VOTE (8683)
- mail by returning a completed
proxy card
- in person at the special meeting
of stockholders
Georgeson, Inc. has been engaged by the Company to serve as
proxy solicitor and can be reached at 1-877-278-9674.
About Zila, Inc.
Zila, Inc., headquartered in Scottsdale, Arizona, is a
diagnostic company dedicated to the prevention, detection and
treatment of oral cancer and periodontal disease. Zila manufactures
and markets ViziLite® Plus with TBlue® (“ViziLite® Plus”), the
company’s flagship product for the early detection of oral
abnormalities that could lead to cancer. ViziLite® Plus is an
adjunctive medical device cleared by the FDA for use in a
population at increased risk for oral cancer. In addition, Zila
designs, manufactures and markets a suite of proprietary products
sold exclusively and directly to dental professionals for
periodontal disease, including the Rotadent® Professional Powered
Brush, the Pro-Select Platinum® ultrasonic scaler and a portfolio
of oral pharmaceutical products for both in-office and home-care
use. All of Zila’s products are marketed and sold in the United
States and Canada primarily through the company’s direct field
sales force and telemarketing organization. The company’s products
are marketed and sold in other international markets through the
direct sales forces of third party distributors. Zila’s marketing
programs reach most U.S. dental offices.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based largely on Zila’s expectations
or forecasts of future events, can be affected by inaccurate
assumptions and are subject to various business risks and known and
unknown uncertainties, a number of which are beyond Zila’s control.
Forward-looking statements include statements that are not
historical facts. The following factors, among others, could cause
actual results to differ from those set forth in the
forward-looking statements: the failure of Zila’s stockholders to
approve the proposed merger transaction; the failure of Zila or
Tolmar to satisfy any other condition to the completion of the
proposed merger transaction; and the risk that the transaction will
be delayed. Additional factors that may affect future results are
discussed in Zila’s Form 10-K for its fiscal year ended July 31,
2008 and Form 10-Q for the quarter ended April 30, 2009. Zila
disclaims any obligation to update and/or revise statements
contained in these materials based on new information or
otherwise.
Additional Information Regarding the Merger
As previously announced, on June 25, 2009, Zila entered into a
definitive Merger Agreement with TOLMAR and on July 28, 2009, Zila
entered into a First Amendment to Agreement and Plan of Merger. On
August 18, 2009, Zila filed with the Securities and Exchange
Commission (“SEC”) a definitive proxy statement relating to the
proposed merger with TOLMAR. These materials were also mailed to
Zila’s stockholders on or about August 19, 2009. STOCKHOLDERS ARE
URGED TO READ THE PROXY STATEMENT AND RELATED MATERIALS IN THEIR
ENTIRETY. SUCH MATERIALS CONTAIN IMPORTANT INFORMATION ABOUT ZILA,
TOLMAR AND THE PROPOSED MERGER TRANSACTION, AND STOCKHOLDERS SHOULD
CAREFULLY CONSIDER THEM BEFORE MAKING ANY VOTING OR INVESTMENT
DECISIONS IN CONNECTION WITH THE PROPOSED MERGER TRANSACTION. The
proxy statement and related materials and any other documents filed
by Zila with the SEC, may be obtained free of charge at the SEC’s
web site, www.sec.gov. In addition, Zila’s stockholders may obtain
free copies of the documents filed by Zila with the SEC by
contacting the Company’s Vice President, General Counsel and
Secretary at Zila, Inc., 16430 North Scottsdale Road, Suite 450,
Scottsdale, Arizona 85254-1770, or by calling (602) 266-6700. This
press release does not constitute an offer of any securities for
sale or the solicitation of any proxy.
Zila, its directors, executive officers and other members of its
management and employees may be deemed to be participants in the
solicitation of proxies from the company’s stockholders in favor of
the proposed merger transaction. Information regarding Zila’s
directors and executive officers and their respective interests in
the proposed merger transaction (which may be different from those
of Zila’s stockholders generally) is included in the proxy
statements and Annual Reports on Form 10-K that Zila has previously
filed with the SEC. The definitive proxy statement relating to the
proposed merger transaction includes information regarding all of
Zila’s participants in the solicitation of proxies in favor of
approving the merger. Stockholders of Zila can obtain free copies
of these documents by using the contact information provided
above.
For more information about Zila and its products, please visit
www.zila.com.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Feb 2025 to Mar 2025
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Mar 2024 to Mar 2025